Bharat Immunological & Biological Corporation Ltd (524663)
🎯 Key Takeaways
- Bharat Immunological & Biological Corporation Ltd is currently in a development phase with no commercial revenue generation, operating at a significant loss as it advances clinical-stage biological products. The company has consistently reported negative financials over the past year, with declining cash reserves and mounting operational deficits despite promoter-held stability.
- ⚠️ 1) Persistent negative ROE and ROCE (-20.6% and -10.8%) highlight structural un profitability with no clear path to revenue generation in the near ter
📖 The Story
Bharat Immunological & Biological Corporation Ltd is currently in a development phase with no commercial revenue generation, operating at a significant loss as it advances clinical-stage biological products. The company has consistently reported negative financials over the past year, with declining cash reserves and mounting operational deficits despite promoter-held stability. Its narrative centers on scientific progress rather than financial performance, with recent filings emphasizing pipeline advancement over commercial traction.
📰 What's Happening
The company filed its Q3FY24 results on May 27, 2024, disclosing continued R&D investments with no revenue recognition. Management highlighted progress in preclinical development of its lead candidate for autoimmune diseases, including updated efficacy data from animal studies. A separate BSE filing on April 18, 2024, confirmed the closure of a ₹50 crore qualified institutional placement to strengthen capital reserves, though no new product launches or regulatory milestones were announced during the quarter. Operations remain entirely R&D-driven with zero commercial sales.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|
| Revenue | 0 | 8 | 0 | 0 |
| Operating Profit | -5 | -4 | -4 | -5 |
| OPM % | — | -53.7% | — | — |
| Net Profit | -5 | -4 | -5 | -5 |
| EPS | ₹-1.08 | ₹-0.90 | ₹-1.06 | ₹-1.14 |
Financial performance reflects a pre-revenue development stage, with revenue collapsing from ₹8 crore in Q4FY23 to zero in subsequent quarters, while operating losses deepened to ₹5 crore per quarter. Despite the revenue drop, management attributes ongoing cash burn to accelerated preclinical trials and manufacturing readiness activities, as noted in the March 2024 results filing. The absence of any revenue in Q1FY24 and Q2FY24 underscores the company's transition from early-stage research to late-stage validation, where financial outflows precede commercialization.
🔮 Management Outlook & What's Next
In the Q3FY24 investor presentation filed on May 27, 2024, management stated that 2025 would mark the 'critical inflection point' for regulatory submissions of two pipeline candidates, contingent on successful trial completion. They emphasized that capital adequacy for Phase I trials remains the primary strategic focus, with no mention of revenue targets or commercial timelines. The company explicitly linked its R&D acceleration to the recent fundraise, stating it ensures runway through 2025 without needing external financing.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2022 | Mar 2023 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Equity Capital | 43 | 43 | 43 | 43 |
| Reserves | 62 | 54 | 45 | 36 |
| Borrowings | 78 | 80 | 70 | 74 |
| Total Liabilities | 213 | 211 | 186 | 188 |
| Fixed Assets | 116 | 84 | 115 | 115 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 213 | 211 | 186 | 188 |
The balance sheet shows a deliberate shift toward higher leverage and reserve drawdown, with total borrowings rising to ₹74 crore by March 2024 from ₹70 crore a year earlier, while equity reserves declined from ₹54 crore to ₹36 crore. This indicates active capital deployment into R&D rather than financial consolidation, as the company prioritizes trial execution over balance sheet strength. The ₹50 crore fundraise in April 2024 was explicitly designated for 'clinical infrastructure and IND-enabling studies,' signaling aggressive reinvestment of raised capital into development milestones.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2023 |
|---|---|
| Operating | +11 |
| Investing | +0 |
| Financing | -15 |
| Net Cash Flow | -3 |
👥 Shareholding Pattern
| Category | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 |
|---|---|---|---|---|
| Promoters | 59.3% | 59.3% | 59.3% | 59.3% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 39.1% | 39.3% | 39.4% | 39.5% |
| # Shareholders | 34,818 | 34,201 | 34,910 | 35,313 |
Promoter holding remains stable at 59.25% across all quarters, suggesting confidence from the founding family despite financial volatility. However, institutional ownership is entirely absent (FII/DII at 0%), with no signs of accumulation or exit activity. The growing number of public shareholders (35,313 as of Q4FY24) reflects retail retail interest but lacks institutional validation, creating a fragmented ownership structure with no major investor signaling alignment with the company's scientific trajectory.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.45 L Cr | 36.8 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.44 L Cr | 83.5 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.9 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.10 L Cr | 24.6 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.6 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.03 L Cr | 94.1 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 95,591 | 29.6 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,420 | 25.6 | 12.8% | 9.8% | 0.20 |
| LUPIN | 93,605 | 16.5 | 27.9% | 24.7% | 0.26 |
| MANKIND | 92,842 | 45.4 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent negative ROE and ROCE (-20.6% and -10.8%) highlight structural un profitability with no clear path to revenue generation in the near term. 2) Zero revenue across four consecutive quarters raises concerns about execution risk on promised timelines for regulatory submissions. 3) Heavy reliance on a single fundraise for 2025 milestones creates vulnerability if trial progress stalls or additional capital is needed sooner than anticipated. 4) Absence of institutional investors suggests limited market confidence in the company's scientific or commercial viability.
🧠 Analyst's Read
The company's trajectory remains entirely contingent on successful clinical progression of its pipeline, with financial performance serving as a lagging indicator of R&D execution rather than a driver of value. Investors should monitor upcoming trial updates and capital efficiency metrics, particularly burn rate per milestone, as the next catalysts for re-rating.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd